Étude intéressante et j'ai hâte que les résultats soient publiés...
"Antiandrogens like cyproterone acetate and spironolactone are prescribed to transgender women in transition by many gynaecologists and endocrinologists (Schneider 2006; Flütsch 2015), and they are commonly considered to be valuable drugs to support transition (WPATH 2011; Hembree 2017). However, clinical evidence suggests that this can result in adverse events; for example, CPA has significant potential for causing depression and for worsening depressive symptoms (Seal 2012). We cannot rule out that CPA contributes to the genesis of other conditions and negatively influences the course of illnesses, including psychiatric, neurological and metabolic disorders (Griard 1978; Ramsay 1990; Oberhammer 1996; Giltay 2000; Calderón 2009; Bessone 2015).
The most common adverse events of spironolactone are hyperkalaemia, dehydration and hyponatraemia (Greenblatt 1973). Furthermore, spironolactone might have an influence on anxiety behavior (Fox 2016).
The adverse events of high estradiol doses described in studies from the 1980s and 1990s should be re‐evaluated because those studies used ethinyl estradiol and premarin (equine estradiol) (Prior 1989), instead of bioidentical 17‐beta‐estradiol, and progestins instead of bioidentical progesterone. Unlike the bioidentical alternatives used today, substances administered in the past (e.g. equine oestrogens, ethinyl estradiol) were associated with diverse adverse effects like thrombophilia, cardiovascular problems, breast and prostate cancer, as well as liver, adrenal gland and neural dysfunction (Griard 1978; Calderón 2009; Asscheman 2011).
The health risks attributed to estradiol doses high enough to suppress androgens have not been found in the parenteral or transdermal application of bioidentical estradiol. Thus it is unclear why those estradiol doses should be kept low in order to make the addition of androgen antagonists like CPA or spironolactone necessary."
Posté le: 23/10/2018 10:58:07 Sujet du message: Publicité